98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/s41375-023-02122-5 | DOI Listing |
Ecohealth
September 2025
Graduate Degree Program in Ecology, Colorado State University, Fort Collins, CO, USA.
Batrachochytrium dendrobatidis (Bd) is a fungal pathogen responsible for dramatic declines of amphibian populations around the world. Experimental exposure studies have documented differences in host susceptibility to Bd, but variation in study designs may limit our ability to compare inferences across studies. Using laboratory-maintained pathogen cultures that may lose virulence over time (i.
View Article and Find Full Text PDFMol Biol Rep
September 2025
Department of Medical Microbiology and Parasitology, Faculty of Medicine, Selangor Branch, Universiti Teknologi MARA (UiTM) Sungai Buloh Campus, Jalan Hospital, Sungai Buloh, 47000, Selangor, Malaysia.
Streptococcus bovis is an opportunistic bacterium consistently associated with colorectal cancer (CRC). This article reviews previous experimental evidence that has successfully demonstrated the role of S. bovis species in the context of CRC.
View Article and Find Full Text PDFMed Oncol
September 2025
Department of Biotechnology, Institute of Engineering and Management, University of Engineering and Management, Kolkata, Kolkata, India.
Oligomeric proanthocyanidins (OPCs), condensed tannins found plentiful in grape seeds and berries, have higher bioavailability and therapeutic benefits due to their low degree of polymerization. Recent evidence places OPCs as effective modulators of cancer stem cell (CSC) plasticity and tumor growth. Mechanistically, OPCs orchestrate multi-pathway inhibition by destabilizing Wnt/β-catenin, Notch, PI3K/Akt/mTOR, JAK/STAT3, and Hedgehog pathways, triggering β-catenin degradation, silencing stemness regulators (OCT4, NANOG, SOX2), and stimulating tumor-suppressive microRNAs (miR-200, miR-34a).
View Article and Find Full Text PDFCancer Immunol Res
September 2025
Alligator Bioscience (Sweden), Lund, Sweden.
Despite recent progress within the field of immuno-oncology, immune suppression in the tumor microenvironment, defective antigen presentation, and low levels of tumor-specific T cells are key limitations of current cancer immunotherapies. CD40-targeting immunotherapies hold promises for addressing these limitations across solid tumors. Here, we describe ATOR-4066, a bispecific antibody that targets CD40 and CEACAM5 developed for immunotherapy of cancer using the Neo-X-Prime platform.
View Article and Find Full Text PDFBiomed Environ Sci
August 2025
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei 230032, Anhui, China;Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, Hefei 230032, Anhui, China;Anhui Prov